Pediatric Chemotherapy-Induced Nausea and Vomiting Workup

1. [Guideline] PDQ® Supportive and Palliative Care Editorial Board. Nausea and Vomiting Related to Cancer Treatment (PDQ®)–Health Professional Version. National Cancer Institute. Available at https://www.cancer.gov/about-cancer/treatment/side-effects/nausea/nausea-hp-pdq. 2023 Jul 20; Accessed: August 3, 2023.

2. Piko B, Bassam A. [Treatment of tumor therapy-induced nausea and vomiting.]. Magy Onkol. 2009 Mar. 53(1):39-45. [QxMD MEDLINE Link].

3. Patel P, Robinson PD, Wahib N, et al. Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Nov. 30 (11):8855-69. [QxMD MEDLINE Link]. [Full Text].

4. [Guideline] Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017 Oct 1. 35 (28):3240-61. [QxMD MEDLINE Link]. [Full Text].

5. [Guideline] Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020 Aug 20. 38 (24):2782-97. [QxMD MEDLINE Link]. [Full Text].

6. Eliasen A, Kornholt J, Mathiasen R, et al. Risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy. J Oncol Pharm Pract. 2022 Aug 29. 10781552221122026. [QxMD MEDLINE Link].

7. Phillips RS, Friend AJ, Gibson F, Houghton E, Gopaul S, Craig JV, et al. Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood. Cochrane Database Syst Rev. 2016 Feb 2. 2:CD007786. [QxMD MEDLINE Link].

8. Czarnetzki C, Elia N, Lysakowski C, et al. Dexamethasone and risk of nausea and vomiting and postoperative bleeding after tonsillectomy in children: a randomized trial. JAMA. 2008 Dec 10. 300(22):2621-30. [QxMD MEDLINE Link].

9. Navari RM. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs. 2009. 69(5):515-33. [QxMD MEDLINE Link].

10. Kang HJ, Loftus S, Taylor A, DiCristina C, Green S, Zwaan CM. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015 Apr. 16 (4):385-94. [QxMD MEDLINE Link].

11. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997 Jan. 15(1):103-9. [QxMD MEDLINE Link].

12. Dupuis LL, Nathan PC. Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children. Paediatr Drugs. 2003. 5(9):597-613. [QxMD MEDLINE Link].

13. Zeltzer LK, Dolgin MJ, LeBaron S, LeBaron C. A randomized, controlled study of behavioral intervention for chemotherapy distress in children with cancer. Pediatrics. 1991 Jul. 88(1):34-42. [QxMD MEDLINE Link].

14. Kelly KM. Complementary and alternative medical therapies for children with cancer. Eur J Cancer. 2004 Sep. 40(14):2041-6. [QxMD MEDLINE Link].

15. American Cancer Society. Nutrition for Cancer Patients; Nausea and Vomiting. American Cancer Society Web Page. Available at http://www.cancer.org/Treatment/SurvivorshipDuringandAfterTreatment/NutritionforPeoplewithCancer/index?sitearea=MBC. Accessed: September 9, 2007.

16. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol. 2007 Feb. 18(2):233-40. [QxMD MEDLINE Link]. [Full Text].

17. Hirota T, Honjo T, Kuroda R, et al. [Antiemetic efficacy of granisetron in pediatric cancer treatment--(2).Comparison of granisetron and granisetron plus methylprednisolone as antiemetic prophylaxis]. Gan To Kagaku Ryoho. 1993 Dec. 20(15):2369-73. [QxMD MEDLINE Link].

18. Holdsworth MT, Raisch DW, Frost J. Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer. 2006 Feb 15. 106(4):931-40. [QxMD MEDLINE Link]. [Full Text].

19. Luisi FA, Petrilli AS, Tanaka C, Caran EM. Contribution to the treatment of nausea and emesis induced by chemotherapy in children and adolescents with osteosarcoma. Sao Paulo Med J. 2006 Mar 2. 124(2):61-5. [QxMD MEDLINE Link].

20. Osoba D, Erlichman C, Willan AR, Levitt M, Pater JL. Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy. Clin Invest Med. 1986 Nov. 9(4):225-31. [QxMD MEDLINE Link].

21. Small BE, Holdsworth MT, Raisch DW, Winter SS. Survey ranking of emetogenic control in children receiving chemotherapy. J Pediatr Hematol Oncol. 2000 Mar-Apr. 22(2):125-32. [QxMD MEDLINE Link].

22. Smith AR, Repka TL, Weigel BJ. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents. Pediatr Blood Cancer. 2005 Nov. 45(6):857-60. [QxMD MEDLINE Link].

23. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol. 2008 Jan. 5(1):32-43. [QxMD MEDLINE Link].

24. Dalzell AM, Bartlett H, Lilleyman JS. Nabilone: an alternative antiemetic for cancer chemotherapy. Arch Dis Child. 1986 May. 61(5):502-5. [QxMD MEDLINE Link].

25. Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics. 1987 Jun. 79(6):946-52. [QxMD MEDLINE Link].

26. Jones E, Koyama T, Ho RH, et al. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy. Pediatr Blood Cancer. 2007 Mar. 48(3):330-2. [QxMD MEDLINE Link].

27. Sepúlveda-Vildósola AC, Betanzos-Cabrera Y, Lastiri GG, Rivera-Márquez H, Villasis-Keever MA, Del Angel VW, et al. Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res. 2008 Aug. 39(6):601-6. [QxMD MEDLINE Link].

28. Jordan K, Roila F, Molassiotis A, Maranzano E, Clark-Snow RA, Feyer P. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. Support Care Cancer. 2011 Mar. 19 Suppl 1:S37-42. [QxMD MEDLINE Link].

29. R. Kadota, V. Shen and Y. Messinger. Safety, pharmacokinetics, and efficacy of palonosetron in pediatric patients: A multicenter, stratified, double-blind, phase 3, randomized study. Journal of Clinical Oncology. June 2007. 25:9570. [Full Text].

30. US Food and Drug Administration (FDA) MedWatch Safety Alert. Ondansetron (Zofran) IV: Drug safety communication – QT prolongation. June 29, 2012. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm310219.htm.

31. Helsinn Healthcare SA. Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients. Clinicaltrials.gov. Available at http://clinicaltrials.gov/ct2/show/NCT01442376.

32. Kovács G, Wachtel AE, Basharova EV, Spinelli T, Nicolas P, Kabickova E. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. Lancet Oncol. 2016 Mar. 17 (3):332-44. [QxMD MEDLINE Link].

Reuven J Schore, MD Associate Professor of Pediatrics, George Washington University School of Medicine and Health Sciences; Attending Physician, Center for Cancer and Blood Disorders, Leukemia and Lymphoma Program, Division of Oncology, Children's National Medical Center

Reuven J Schore, MD is a member of the following medical societies: American Society of Hematology, American Society of Pediatric Hematology/Oncology

Disclosure: Received research grant from: Jansen Inc<br/>Received income in an amount equal to or greater than $250 from: Jazz Pharmecuticals.

Devona Williams, PharmD Pharmacy Clinical Specialist, Children's National Medical Center

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Max J Coppes, MD, PhD, MBA Executive Vice President, Chief Medical and Academic Officer, Renown Heath

Max J Coppes, MD, PhD, MBA is a member of the following medical societies: American College of Healthcare Executives, American Society of Pediatric Hematology/Oncology, Society for Pediatric Research

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article